Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

NCT04317534 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

244

Enrollment

OTHER

Sponsor class

Conditions

NSCLC, Stage I

Interventions

DRUG: Pembrolizumab

Sponsor

Greg Durm, MD

Collaborators

[object Object]